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Chemotherapy may offer effective palliation in the management of metastatic breast cancer (MBC). Anthracyclinefbased regimens are still 
considered a standard therapy for MBC. However, the 
increasing use of anthracyclines during the adjuvant setf
ting necessitates the search for novel combinations to eff
fectively treat patients who develop metastatic disease. 
 Vinorelbine administered intravenously generates a 
consistent level of activity, with overall response rates 
ranging from 35% to 50% and a highly acceptable toxicf
ity profile.1f8 Capecitabine is an oral fluoropyrimidine 
that preferentially delivers fluorouracil to the tumor. 
Approved in 1998 as treatment for MBC refractory 
to paclitaxel and anthracyclines, capecitabine induces 
Combination of oral vinorelbine and 
capecitabine in the treatment of metastatic 
breast cancer patients previously exposed to 
anthracyclines: a pilot study
Mohammad Hassan, Mahmoud M. Osman
from the oncology department, erfan hospital, Jeddah, saudi arabia
correspondence: mohammad hassan md · oncology department, erfan hospital, al steen st., po box 6519, Jeddah 21452, saudi arabia · 
hassanv220000@yahoo.com · accepted for publication: december 2010
hematol oncol stem cell ther 2010; 3(4): 185-190
doi: 10.5144/1658-3876.2010.185
BACKGROUND AND OBJECTIVES: Vinorelbine and capecitabine are both active in breast cancer with moderate 
toxicity.  
DESIGN AND SETTING: a pilot study conducted from december 2007 to January 2010 in patients with metastatic 
breast cancer (mbc) to the evaluate efficacy and safety of combination therapy with vinorelbine and capecitabine.
PATIENTS AND METHODS: the study included patients with mbc who were previously treated by anthracyclines 
either during the adjuvant phase or the metastatic phase. patients were treated with oral vinorelbine (60 mg/m2) 
on day 1+8 and capecitabine (1000 mg/m2) twice daily (Vc) from day 1 to day 14 with both repeated every 3 
weeks until progression, refusal or for a maximum of 8 cycles. a dose reduction was made in case of grade 3 and 
4 toxicities. 
RESULTS:  of 31 women (median age, 51 years), 12 cases were first-line therapy and 19 cases were second-line 
therapy or greater, and 30 were evaluable for response. two patients (6.4%) achieved complete response and 15 
patients (48.4%) had a partial response giving an overall response rate of 54.8% (95% ci, 42%-68%). time-to-
disease progression was 7.8 months for patients receiving Vc as first-line therapy versus 6 months for patients 
receiving Vc as second-line therapy or more, while median survival time was 22 months and 10 months for the 
two groups, respectively. 
CONCLUSIONS:   the oral Vc regimen is effective and safe in patients with mbc previously exposed to anthracy-
clines, and offers a promising alternative to the intravenous route. its role as a salvage therapy following anthracy-
cline failure or as first-line chemotherapy requires further study. 
objective response rates of 20% to 36%, and a median 
survival of more than 1 year.9f14
The therapeutic activity of the combination of fluof
rouracil with vinorelbine in MBC has already been 
tested by other investigators in six phase II studies. In 
two studies, fluorouracil was administered in bolus,15f16 
whereas in the other four studies, it was administered as 
a continuous infusion over 3 to 5 days.17f20 Overall, the 
combination achieved high response rates (up to 70% as 
firstfline approach), but tolerance was not satisfactory 
(grade 3/4 leukopenia was observed in a high percentf
age [20% to 90%] of cases).
Considering the efficacy of the combination of 5fFU 
and vinorelbine, in the previous studies and the substif
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tution of 5fFU (with or without leucovorin) by the oral 
administration of capecitabine may provide a convef
nient alternative in the treatment of advanced breast 
cancer.13 In fact, the greater acceptability of oral versus 
intravenous agents in this clinical setting has been firmf
ly established.21 The potential advantages of oral chef
motherapy agents, which include ease of administraf
tion and reduced need for hospitalization, are likely to 
provide a useful contribution to improvement of care, 
as long as an equivalent level of efficacy is maintained.
The combination of vinorelbine and capecitabine 
(VC) may have some potential benefits, as the two 
drugs have different mechanisms of action and resisf
tance with a rather nonfoverlapping toxicity profile.22 
The presence of synergy between the two drugs on 
some cancer cell lines had been reported.23 The aim of 
this pilot study was to evaluate the efficacy and toxicf
ity of VC regimen in patients with MBC previously 
exposed to anthracyclines. 
PATIENTS AND METHODS
Thirtyfone patients with MBC were included in this 
study that was conducted from August 2007 to January 
2010. Eligibility criteria included histologically (or cyf
tologically) confirmed breast cancer with at least one 
measurable metastatic site. All patients had to be previf
ously treated by an anthracyclinefbased regimen (doxof
rubicin or epirubicin) during either the adjuvant or 
the metastatic phase of the disease. Eligibility criteria 
also entailed an Eastern Cooperative Oncology Group 
(ECOG) performance status ≤2 and a definite failure 
of hormonal therapy in hormone receptor (+ve) paf
tients. In addition, patients had to have a platelet count 
≥100 000/mm3, hemoglobin ≥10/dL, and an absolute 
neutrophil count >1500/mm3, with adequate cardiac, 
renal and hepatic function. Informed consent was obf
tained in all patients. Patients with overexpressed Herf
2 receptors and CNS metastatic disease at the time of 
enrollment were excluded from the study.
Patients were considered to be anthracycline ref
sistant if they had disease progression during prior 
anthracyclinefbased treatment, whether in metastatic 
or adjuvant phase (primary resistant), or those who 
progressed within 3 months of completing anthracyf
clinefbased treatment for metastatic disease or within 
6 months of completing anthracyclinefbased treatment 
during adjuvant phase (secondary resistant). Otherwise, 
patients were considered to be anthracycline sensitive.24 
Pretreatment assessment included medical history 
(with all the details of prior treatment), physical exf
amination, CBC/platelet, routine biochemical profile 
including a CA15f3 assay. Metastatic workup included 
isotopic bone scan, CT of the chest, abdomen and pelf
vis.  Any other images were done when appropriately 
indicated. Clinical examination, blood count, liver enf
zymes, serum creatinine and CA15f3 were performed 
on a 3 weekly basis, while baseline radiological images 
were performed following the third and sixth cycles of 
chemotherapy, at the end of the treatment course, and 
every 3 months during follow up.
The VC regimen consisted of oral vinorelbine (60 
Table 1. Characteristics of 31 women with metastatic breast 
cancer.
Number of 
cases %
Age (years)
     range 28-72
     Median 51
Performance status 
score
     0-1 17 53
     2 14 47
Prior anthracycline 
     Adjuvant 19 61
     Metastatic 12 39
     resistant 12 39
Hormone receptors
     positive 18 58
     Negative 10 32
     Unknown 3 10
No metastatic sites
     One site 10 32
     More than one 21 68
Metastatic site
     All visceral site 22 71
     Liver 10 32
     Lung 13 41
     Others 14 48
     Bones 16 52
Chemotherapy line
     First-line 12 39
     One-line 15 48
     2nd line or more 4 13
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mg/m²) on day 1+8 and capecitabine (1000 mg/m²) 
twice daily from day 1 to day 14, with both drugs ref
peated every 3 weeks. Oral antiemetic therapy and H2 
blockers were given for all patients. In case of grade 3 
or 4 toxicity, a 25% dose reduction of the two drugs 
was made in subsequent cycles. Assessment for antif
tumor activity was made according to World Health 
Organization criteria.25 while toxicity was assessed 
according to the National Cancer Institute Common 
Toxicity Criteria (NCIfCTC; version 3.0).26 Treatment 
was continued for a maximum of 8 cycles, provided 
there was no disease progression or the patient refused. 
The primary objective of this study was to assess the 
efficacy of this combination by determining overall ref
sponse rate. Secondary endpoints were the assessment 
of the toxicity of the VC regimen as well as the timef
tofdisease progression and the survival at one year. 
 Time to disease progression was calculated from 
the date of first treatment course to the date of docuf
mented disease progression. Survival was the interval 
between the date of the start of treatment and the date 
of death. If a patient was lost to followfup, that patient 
was censored as of the date of last contact.
The descriptive analysis was done using an IBM 
compatible computer and Statistics 6.0 for Windows 
XP statistical package. Overall survival was estimated 
by the Kaplan Meier method. Comparison of survival 
curves was done by Log Rank test.
RESULTS
The characteristics of the 31 included patients are 
listed in Table 1. The majority of patients (71%) had 
visceral metastasis, while 68% had 2 or more metaf
static sites. Performance status (PS) according to the 
ECOG score was 0f1 in 53% and 2 in 47%. All patients 
received a prior anthracyclinefbased regimen during eif
ther the adjuvant phase (61%) or metastatic phase of 
the disease (39%). Twelve patients (39%) were considf
ered anthracycline resistant. The median time from last 
anthracycline treatment to inclusion in the study was 7 
months. Nineteen cases (61%) had received the study 
regimen as a secondf or thirdfline treatment for their 
metastatic disease. During the study period, a total of 
159 cycles were administered with a median of 6 cycles 
per patient. In 42 cycles (26%) there was 25% dose ref
duction of the two drugs. A delay of treatment with 
both drugs not more than 4 days occurred in 22% of 
the cycles.
Common grade 3f4 toxicities observed were hand 
and foot syndrome in 7 patients (22.5%), neutropenia 
in 5 patients (16%) with 2 of the latter (6.4%) develf
oping febrile neutropenia. Other grade 3f 4 toxicities 
included thrombocytopenia (9.6%), anemia (6.4%), 
diarrhea in (12.9%), vomiting (3.2%), oral mucositis 
(3.2%) and fatigue in (6.4%). Toxicity was more obf
served in patients that received VC as secondf or thirdf
line therapy (Table 2).
Among the 31 included patients, 30 were considf
ered valuable for response as one patient refused to 
continue treatment after she received the first week 
of treatment due to grade 3 vomiting. The overall ref
sponse rate (intent to treat) was 54.8% (95% CI: 42%f
68%). Two patients (6.4%) achieved complete response 
(CR), 15 cases (48.4%) achieved partial response (PR), 
with a median duration of response of 10.5 months. 
Six cases (19%) had disease stability, with control of 
the disease in 74% while 8 cases (26%) progressed on 
treatment (Table 3).
Grade 3-4 toxicities Number %
Hematological
   Neutropenia 5 16
   Febrile neutropenia 2 6.4
   Thrombocytopenia 3 9.6
   Anemia 2 6.4
Nonhematological
   Hand and foot syndrome 7 22.4
   Diarrhea 4 12.6
   Mucosites 1 3.2
   Vomiting 1 3.2
   Fatigue 2 6.4
   Myalgia 1 3.1
Table 2. Common grade 3-4 toxicities.
Table 3.  response rates in 31 women with metastatic breast cancer.
 
 
 
Total
n=31
First-line or more Anthracycline resistance
1st
n=12
2nd
n=19
Sensitive
n=19
Resistant
n=12
Complete response 2 2 0 2 0
partial response 15 6 9 10 5
Stable disease 6 2 4 4 2
Disease progression 7 2 5 2 5
Not evaluable 1 0 1 1 0
Overall response 
rate
54.8% 
(17/31) 67% 47% 63% 41%
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Among the 12 cases who received the VC regimen 
as firstfline therapy, 8 cases (67%) had an objective 
response versus 9 (47%) in the 19 patients receiving 
their treatment as secondfline or greater therapy (no 
CR were seen in the latter group). The response rate 
was also superior in anthracyclinefsensitive patients 
(63%) compared to those with anthracycline resistance 
(42%). 
The median timeftofprogression for the 12 patients 
who received the VC combination as firstfline therapy 
was 7.8 months compared to 6 months among the 19 
patients who received the combination as a secondf or 
thirdfline therapy. The 19 patients who were anthraf
cycline sensitive had 7.8 months median timeftofprof
gression compared to 6 months in the 12 patients who 
were anthracycline resistant. The median survival time 
for the whole group was 13 months with a range of 2 
to 43 months and the actuarial onefyear survival was 
53% (Figure 1). The median survival time for the 12 
patients who received the VC combination as firstf
line was 21 months with a range of 4 to 43+ months 
compared to 10 months (range, 2f21 months) among 
those who received the combination as secondf or 
thirdfline. The median survival time was 17 months 
among patients who were anthracycline sensitive verf
sus 10 months among those who were resistant to anf
thracycline. Patients who were anthracyclinefsensitive 
showed 1f and 2fyear actuarial overall survival of 56% 
and 21%, respectively, compared to 42% and 9% for 
those who were anthracycline resistant. 
DISCUSSION
In chemotherapyfnaive patients anthracyclinef and/or 
taxanefbased regimens have significant efficacy. It is 
important to note that the widespread use of anthraf
cyclines and taxanes in the adjuvant setting has led to 
an increasing number of patients presenting with adf
vanced disease that is resistant to both drugs. In this 
population, treatment options remain controversial bef
cause no standard chemotherapy has been defined, and 
there is a need for the testing of new effective regimens 
with a favorable therapeutic index. Patients who have 
progressive disease during or immediately after adjuf
vant anthracycline treatment have a poor prognosis 
and a small chance of achieving an objective response 
when treated with other cytotoxic agents.24,27 
The present study comprised a relatively small numf
ber of patients with MBC whose pretreatment charf
acteristics seemed to be predictive of a less favorable 
outcome. Among them, two or more previous chemof
therapy lines and visceral metastases have been clearly 
shown to be related to a poor outcome.27 The only faf
vorable prognostic parameter was the relatively good 
performance status. In this setting, the VC combinaf
tion showed considerable activity, with an overall ref
sponse rate of 54.8% and a CR rate of 6.4%. Responses 
were seen in soft tissue and visceral sites, as well as in 
patients with one site or more sites involvement.
It is well known that the extent of previous therapies 
will usually influence the results of the protocol treatf
ment. Accordingly, this study yielded a higher overall 
response rate (67%) in patients who received the VC 
regimen as firstfline, versus 42% in those receiving 
their treatment as secondfline or higher therapy (no 
CR were seen in the latter group). However, the more 
than 40% response rate obtained in the latter cases was 
noteworthy, because it seemed to be higher than exf
pected in a heavily pretreated patient population.24,28
The responses achieved were durable. The median 
survival time for the 12 patients who received VC comf
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Figure 1. Overall survival for the whole group.
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Figure 2. Overall survival by first-line and second-line or greather 
therapy.
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bination as firstfline line was 21 months with (range, 
4f43+) compared to 10 months (range, 2f21 months) 
among those who received the combination as secondf 
or thirdfline therapy. The latter finding was unexpectf
edly high, considering the poor prognosis and the chef
moresistance of the patients enrolled. The relatively 
good performance status of the enrolled patients and 
the long duration of the responses obtained may have 
been both contributory. However, this result must be 
confirmed in large randomized trials.
As expected the efficacy data in our study demf
onstrated inferior results in anthracyclinefresistant 
compared to anthracyclinefsensitive patients, but the 
small sample size of our study does not allow for a relif
able subgroup analysis. The results of the study clearly 
showed that the combination regimen seems to be 
non–crossfresistant to anthracyclines and represents 
a valid option to be tested in randomized studies for 
patients with primary resistance to anthracyclines in 
an adjuvant setting or in metastatic disease or in paf
tients with progressive disease after discontinuation of 
anthracyclinefbased chemotherapy.24 
The non–crossfresistance of vinorelbine with 
respect to anthracyclines has been reported repeatf
edly.29,30 However, it is unlikely that oral vinorelbine 
alone can yield such results, because its reported acf
tivity in anthracyclinefresistant patients has not exf
ceeded 30%.29,31 Similarly, the response rate obtained 
with capecitabine as a secondf or thirdfline approach 
in metastatic breast cancer was 20% to 33%.13,14 
Therefore, the high response rate of oral vinorelbine 
and capecitabine in the present study was probably due 
to in vivo synergism between the two drugs rather than 
an overlapping effect.
It is noteworthy that the high therapeutic activity 
of the capecitabine and vinorelbine combination has 
already been described by other investigators,32f34 with 
almost comparable efficacy and safety. Nole et al32 adf
ministered capecitabine at a dose of 1000 mg/m2 twice 
daily for 2 weeks in combination with vinorelbine at a 
dose of 6o mg/m2 oral on days 1, 8 and 15.The overall 
response rate was 44.2% and the progressionffree surf
vival and overall survival were 8 and 25 months, respecf
tively. The main toxicity was neutropenia. Welt et al33 
reported that the overall response rate for capecitabine 
and vinorelbine was 55% (95% CI, 36% to 72.7%),and 
the median time to disease progression was 8 months 
(95% CI, 4.3f11.7) with an overall survival of 19.2 
months (95% CI, 11.3f27.1), but Vinorelbine was givf
en intravenously at escalated doses of 25mg/m2 (dose 
level 1) and 30 mg/m2 (dose level 2) on days 1 and 8, 
and 22 and 2 and neutropenia (grade 3 and 4) was obf
served in 39% of patients. Finek et al34 in another study 
using the same dose of capecitabinne and vinorelbine, 
reported a response rate of 56.5%, but all the patients 
were receiving it as firstfline therapy after failure of anf
thracycline.
The toxicity of this combination seems to be even 
less than that obtained in published data for the two 
drugs used as single agents.6f8,11,12,14 In particular, the 
combination regimen in our study resulted in mild hef
matologic toxicity, because grade 3/4 neutropenia was 
found in only 16% of cases, compared with 20% to 49% 
reported in others studies.32f35 The low dosefintensity 
adopted for each drug and the absence of an overlapf
ping toxicity profile could account for the better tolerf
ability of this regimen.
In summary, the oral VC regimen is  an effective and 
safe regimen in MBC patients previously exposed to 
anthracyclines, and offers a promising alternative to the 
intravenous route. Its role as a salvage therapy followf
ing anthracycline failure or as firstfline chemotherapy 
requires further large or randomized studies.
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